Skip to main content
. 2022 Jul 13;65(14):9718–9734. doi: 10.1021/acs.jmedchem.2c00142

Figure 6.

Figure 6

Effects of synthesized compound treatment on AGTwt and the G41R variant expressed in mammalian cells. CHO-GO-AGTwt and CHO-GO-AGT-G41R cells were grown for 7 days in the presence of 50 μM of each compound, as indicated. At the end of treatment, cells were detached and lysed, and the soluble fraction of the lysate was used for (A) transaminase activity determination. The specific activity of AGT in CHO-GO-AGTwt control cells (191 ± 10 nmol of pyruvate/min/mg protein) and in CHO-GO-AGT-G41R control cells (6.8 ± 0.7 nmol of pyruvate/min/mg protein) was assumed to be 1 to help assess the changes. Data represent mean ± SEM (n = 7). *p < 0.05 vs control cells. (B) AGT protein level quantification by western blot. AGT levels in CHO-GO-AGTwt and CHO-GO-AGT-G41R control cells were assumed to be 1 to help assess the changes. GAPDH has been used as the loading control. The images are representative of one out of three separate experiments. Data represent mean ± SEM (n = 4). *p < 0.05 vs control cells.

HHS Vulnerability Disclosure